- Home
- SGLY vs IMNN Comparison
SGLY vs IMNN Comparison
Compare SGLY & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- IMNN
- Stock Information
- Founded
- SGLY 2001
- IMNN 1982
- Country
- SGLY United States
- IMNN United States
- Employees
- SGLY N/A
- IMNN N/A
- Industry
- SGLY
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- IMNN Health Care
- Exchange
- SGLY Nasdaq
- IMNN Nasdaq
- Market Cap
- SGLY 3.9M
- IMNN 12.1M
- IPO Year
- SGLY 2008
- IMNN 1985
- Fundamental
- Price
- SGLY $1.11
- IMNN $0.77
- Analyst Decision
- SGLY
- IMNN Buy
- Analyst Count
- SGLY 0
- IMNN 2
- Target Price
- SGLY N/A
- IMNN $14.00
- AVG Volume (30 Days)
- SGLY 53.3K
- IMNN 2.3M
- Earning Date
- SGLY 08-26-2025
- IMNN 08-13-2025
- Dividend Yield
- SGLY N/A
- IMNN N/A
- EPS Growth
- SGLY N/A
- IMNN N/A
- EPS
- SGLY N/A
- IMNN N/A
- Revenue
- SGLY $2,172,036.00
- IMNN N/A
- Revenue This Year
- SGLY N/A
- IMNN N/A
- Revenue Next Year
- SGLY N/A
- IMNN N/A
- P/E Ratio
- SGLY N/A
- IMNN N/A
- Revenue Growth
- SGLY N/A
- IMNN N/A
- 52 Week Low
- SGLY $0.54
- IMNN $0.37
- 52 Week High
- SGLY $7.65
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- SGLY 59.35
- IMNN 40.86
- Support Level
- SGLY $0.93
- IMNN $0.70
- Resistance Level
- SGLY $1.10
- IMNN $0.86
- Average True Range (ATR)
- SGLY 0.08
- IMNN 0.10
- MACD
- SGLY -0.01
- IMNN -0.05
- Stochastic Oscillator
- SGLY 78.26
- IMNN 10.34
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).